home / stock / dyn / dyn articles

DYN Articles, Dyne Therapeutics Inc. - From 07/14/24

Stock Information
Company Name: Dyne Therapeutics Inc.
Stock Symbol: DYN
Market: NYSE
Website: dyne-tx.com
Menu
DYN DYN Quote DYN Short DYN News DYN Articles DYN Message Board
Get DYN Alerts

News, Short Squeeze, Breakout and More Instantly...
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details | Benzinga

These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped...
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday | Benzinga

U.S. stocks were higher, with the Nasdaq Composite gaining over 250 points on Wednesday. Shares of Casey’s General Stores, Inc. (NASDAQ:CASY)...

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference | Benzinga

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advanc...

Why Is Dyne Therapeutics Stock Soaring On Monday? | Benzinga

Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with m...
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday | Benzinga

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Monday. Shares of Overseas Shipholding Group, Inc. (NYSE:OSG) rose ...

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints | Benzinga

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 M...

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET | Benzinga

WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advan...
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium | Benzinga

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) an...

Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday | Benzinga

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of Aehr Test Systems (NASDAQ: AEHR) fell sharply duri...
Previous 10 Next 10